Diagnosing idiosyncratic drug-induced liver injury: lessons from monocyte-derived hepatocyte-like cells

Developing <i>in vitro</i> models that incorporate immunological aspects of iDILI susceptibility is essential for advancing hepatotoxicity research as an alternative to animal testing, aligning with the Food and Drug Administration (FDA) Modernization Act 2.0. Peripheral blood monocyte-derived hepatocyte-like cells, particularly when incorporated into multicellular organoid systems, offer a valuable opportunity to mimic the polygenic architecture of drug susceptibility, enabling the investigation of a compound's DILI potential and underlying mechanisms.